Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Oct 5:9:1026521.
doi: 10.3389/fmed.2022.1026521. eCollection 2022.

The dual role of CD6 as a therapeutic target in cancer and autoimmune disease

Mikel Gurrea-Rubio  1 , David A Fox  1
Affiliations
Review

The dual role of CD6 as a therapeutic target in cancer and autoimmune disease

Mikel Gurrea-Rubio et al. Front Med (Lausanne). .

Abstract

Autoimmune disease involves loss of tolerance to self-antigen, while progression of cancer reflects insufficient recognition and response of the immune system to malignant cells. Patients with immune compromised conditions tend to be more susceptible to cancer development. On the other hand, cancer treatments, especially checkpoint inhibitor therapies, can induce severe autoimmune syndromes. There is recent evidence that autoimmunity and cancer share molecular targets and pathways that may be dysregulated in both types of diseases. Therefore, there has been an increased focus on understanding these biological pathways that link cancer and its treatment with the appearance of autoimmunity. In this review, we hope to consolidate our understanding of current and emerging molecular targets used to treat both cancer and autoimmunity, with a special focus on Cluster of Differentiation (CD) 6.

Keywords: ALCAM (CD166); CD318; CD6; CD8 lymphocytes+; NK cells; autoimmunity; cancer.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Schematic representation of the role of anti-CD6 (UMCD6) in cancer and autoimmunity. (A) Internalization of CD6 on CD8+ T cells and NK cells with UMCD6 induces the activation of these cells by up-regulation of granzyme-b, perforin and the activating receptors NKG2D, and down-regulation of the inhibitory receptor NKG2A. (B) UMCD6 provides a protective effect in autoimmune diseases by suppression of differentiation of effect Th1 and Th17 cells.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Baghban R, Roshangar L, Jahanban-Esfahlan R, Seidi K, Ebrahimi-Kalan A, Jaymand M, et al. . Tumor microenvironment complexity and therapeutic implications at a glance. Cell Commun Signal. (2020) 18:59. 10.1186/s12964-020-0530-4 - DOI - PMC - PubMed
    1. Bolon B. Cellular and molecular mechanisms of autoimmune disease. Toxicol Pathol. (2012) 40:216–29. 10.1177/0192623311428481 - DOI - PubMed
    1. Laine A Labiad O Hernandez-Vargas H This S Sanlaville A Leon S . Regulatory T cells promote cancer immune-escape through integrin alphavbeta8-mediated TGF-beta activation. Nat Commun. (2021) 12:6228. 10.1038/s41467-021-26352-2 - DOI - PMC - PubMed
    1. Shang B, Liu Y, Jiang SJ, Liu Y. Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis. Sci Rep. (2015) 5:15179. 10.1038/srep15179 - DOI - PMC - PubMed
    1. Li T, Yang Y, Hua X, Wang G, Liu W, Jia C, et al. . Hepatocellular carcinoma-associated fibroblasts trigger NK cell dysfunction via PGE2 and IDO. Cancer Lett. (2012) 318:154–61. 10.1016/j.canlet.2011.12.020 - DOI - PubMed